Free Trial

Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical logo with Medical background

Journey Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totalling 76,700 shares, a decline of 12.5% from the September 30th total of 87,700 shares. Based on an average daily volume of 62,700 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.8% of the company's stock are sold short.

Journey Medical Price Performance

Shares of DERM stock traded down $0.26 during trading hours on Tuesday, hitting $5.74. 80,044 shares of the company's stock were exchanged, compared to its average volume of 117,298. The stock's 50-day moving average is $5.42 and its 200-day moving average is $4.88. The company has a debt-to-equity ratio of 1.75, a current ratio of 1.36 and a quick ratio of 1.08. The stock has a market cap of $114.87 million, a price-to-earnings ratio of -19.35 and a beta of 0.92. Journey Medical has a 52 week low of $2.85 and a 52 week high of $8.11.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $14.86 million for the quarter, compared to the consensus estimate of $13.81 million. Journey Medical had a return on equity of 5.44% and a net margin of 1.09%. During the same quarter in the previous year, the company posted ($0.46) EPS. As a group, research analysts forecast that Journey Medical will post -1.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DERM. Rodman & Renshaw began coverage on Journey Medical in a report on Thursday, August 22nd. They set a "buy" rating and a $9.00 price target for the company. Lake Street Capital began coverage on Journey Medical in a report on Friday, September 6th. They set a "buy" rating and a $9.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $9.38.

Read Our Latest Analysis on DERM

Insider Buying and Selling at Journey Medical

In other Journey Medical news, CFO Joseph Benesch sold 9,324 shares of the business's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $5.47, for a total value of $51,002.28. Following the transaction, the chief financial officer now owns 47,331 shares in the company, valued at $258,900.57. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 19.42% of the company's stock.

Hedge Funds Weigh In On Journey Medical

Several large investors have recently made changes to their positions in DERM. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Journey Medical during the second quarter valued at $1,664,000. Acadian Asset Management LLC lifted its stake in shares of Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company's stock valued at $817,000 after acquiring an additional 194,389 shares during the period. PVG Asset Management Corp acquired a new position in shares of Journey Medical during the second quarter valued at $894,000. Rosalind Advisors Inc. acquired a new position in shares of Journey Medical during the second quarter valued at $644,000. Finally, Heron Bay Capital Management acquired a new position in shares of Journey Medical during the first quarter valued at $124,000. Institutional investors and hedge funds own 7.25% of the company's stock.

Journey Medical Company Profile

(Get Free Report)

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Let’s be blunt (From DTI) (Ad)

Should you invest $1,000 in Journey Medical right now?

Before you consider Journey Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.

While Journey Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines